Navigation Links
Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
Date:2/6/2009

ST. LOUIS, Feb. 6 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2008, on Thursday, February 26, 2009 before the market opens. The Company will host a conference call and webcast on Thursday, February 26, 2009 at 8:30 a.m. Eastern Time to discuss the Company's fourth quarter results and current corporate developments. The dial-in number for the conference call is 800-240-2134 for domestic participants and 303-275-2170 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using passcode 11125670#. The call will also be available on the Internet live and 90 days thereafter at the following URL: http://www.videonewswire.com/event.asp?id=55849

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Stereotaxis Showcases Advancements for Remote Magnetic Ablations
2. Stereotaxis Appoints Senior Vice President, North America
3. Stereotaxis to Present at the Seventh Annual JMP Securities Research Conference
4. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
7. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
8. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
9. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
11. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a ... from the National Institute of Mental Health (NIMH) for the further advancement of the ... PROZOR technology and is expected to deliver therapeutic levels of olanzapine for a ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... PANAMA CITY , Jan. 26, 2017  Crossmatch, ... today unveiled a new solution aimed at combatting fraud, ... The solution was introduced at the Action on Disaster ... a key meeting point for UN agencies and foreign ... Fraud, waste and abuse are a largely ...
Breaking Biology News(10 mins):